7th Cancer Cachexia Conference
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
8:00 am |
Welcome and Introductory Remarks CCS President Teresa Zimmers, PhD, Oregon Health & Science University, USA |
|
Clinical Advances in Cancer Cachexia |
|
|
Session A: State-of-the-Knowledge: Clinical Fundamentals of Cancer Cachexia Co-Chairs: TBN |
|
|
8:10 am |
Objective metrics for cancer cachexia assessments TBN |
|
8:40 am |
Cancer cachexia clinical trial endpoints Barry Laird, MBChB MRCGP MD - University of Edinburgh, Scotland, UK |
|
9:10 am |
Update on consensus definition of cancer cachexia Vickie Baracos, PhD - University of Alberta, CANADA |
|
9:40 am |
Cardiac wasting in advanced cancer & its therapeutic implications Stefan Anker, PhD & MD - Charité Berlin, GERMANY |
|
10:10 am |
Break |
|
Session B: Recent Clinical Trials and Trial Results Co-Chairs: TBN |
|
|
10:30 am |
Trial design, efficacy, safety, and tolerability of ponsegromab in cancer cachexia John D. Groarke, MBBCh MSc MPH – Pfizer, Inc. |
|
11:00 am |
Central relays in cancer cachexia Daniel Marks, MD & PhD – Oregon Health & Science University, USA |
|
11:30 am |
Talk selected from abstract submissions |
|
12:00 pm |
Short talk – Developing a Cachexia Lexicon Elif Andac-Jones, PhD - Cancer Support Community, USA |
|
12:15 pm |
Short talk selected from abstract submissions |
|
12:30 pm |
Lunch Break |
|
Considering People with Cancer Cachexia |
|
|
1:30 pm |
Patient-Provider-Caregiver Panel Chair: Martin Kochanczyk, PhD – Cancer Cachexia Society, USA
|
|
History of Cancer Cachexia Research in Scotland |
|
|
Chair: TBN |
|
|
3:00 pm |
History of cancer cachexia research in Glasgow Donald McMillan, PhD – University of Glasgow, Scotland, UK |
|
3:25 pm |
History of cancer cachexia research in Edinburgh Steve Wigmore, MBBS, MD – University of Edinburgh, Scotland, UK |
|
3:45 pm |
Break |
|
Next Gen Researchers in Cancer Cachexia |
||
|
Co-Chairs: Andrea Bonetto, PhD – University of Colorado, USA and Maria Rohm, PhD - Helmholtz Center Münich, GERMANY
|
||
|
4:00 pm |
NextGen Talk 1 from submissions |
|
|
4:15 pm |
NextGen Talk 2 from submissions |
|
|
4:30 pm |
NextGen Talk 3 from submissions |
|
|
4:45 pm |
NextGen Talk 4 from submissions |
|
|
5:00 pm |
NextGen Talk 5 from submissions |
|
|
5:15 pm |
NextGen Talk 6 from submissions |
|
|
5:30 pm |
*Social Events
Whisky tasting Ghost tour of Edinburgh Walking tour of Edinburgh |
|
Friday, September 29, 2023
|
7:00 am |
Mentoring Event |
|
|
NCI/CRUK Cancer Grand Challenge - CANCAN |
||
|
Chair: Bette Caan, DrPH - Kaiser Permanente, USA |
||
|
8:30 am |
CANCAN talk 1 Sheng Tony Hui, PhD – Harvard University, USA |
|
|
9:00 am |
CANCAN talk 2 Janelle Ayres, PhD – Salk Institute for Biological Studies, USA |
|
|
9:30 am |
CANCAN talk 3 David Lewis, PhD - Beatson Institute, Scotland, UK |
|
|
9:45 am |
Working Towards a Precision Medicine Framework in Cancer Cachexia: Learning from Patients Richard Dunne, MD - University of Rochester, USA |
|
|
10:30 am |
Break |
|
|
Tumor as driver of cachexia |
||
|
Co-Chairs: TBN |
||
|
11:00 am |
Talk title to be confirmed Min Li, PhD – The University of Oklahoma Health Sciences Center |
|
|
11:30 am |
Heterogeneity of lung cancer and cachexia in mouse models Rodney Infante, MD PhD - University of Texas Southwestern Medical Center, USA |
|
|
12:00 pm |
Racial/Ethnic heterogeneity Jose Trevino, MD - Virginia Commonwealth University, USA |
|
|
12:30 pm |
Short talk selected from abstracts |
|
|
12:45 pm |
Lunch break |
|
|
1:30 pm |
Poster Viewing |
|
|
Cachexia/Muscle wasting as a driver of cancer |
||
|
Co-Chairs: TBN |
||
|
4:00 pm |
Muscle growth slows tumor growth Bert Blaauw, PhD - Veneto Institute of Molecular Medicine, ITALY |
|
|
4:30 pm |
Host Murf1 deletion preserves muscle and slows pancreatic cancer progression Andrew Judge, PhD - University of Florida, USA |
|
|
5:00 pm |
Effects of Murf1 host deletion on tumor microenvironment Jason Doles, PhD - Indiana University, USA |
|
|
5:15 pm |
Short talk selected from abstracts |
|
|
5:30 pm |
Short talk selected from abstracts |
|
|
7:00 pm |
*Dinner |
|
|
9:00 pm |
*Cèilidh – a traditional Scottish party |
|
Saturday, September 30, 2023
|
7:00 |
Social Event |
|||
|
Multi-organ crosstalk in Cancer Cachexia |
||||
|
Co-Chairs: TBN |
||||
|
8:30 am |
Gut microbiome alterations and metabolic disorders in acute myeloid leukemia Laure Bindels, PhD - Université catholique de Louvain, BELGIUM |
|||
|
9:00 am |
Tumor - host interactions revealed in drosophila models of cachexia Tor Erik Rusten, PhD – University of Oslo, NORWAY |
|||
|
9:30 am |
Short talk selected from abstract submissions |
|||
|
9:45 am |
Short talk selected from abstract submissions |
|||
|
10:00 am |
Break |
|||
|
Keynote Address |
||||
|
10:15 am |
Introduction of Kenneth Fearon Lecture Speaker Marie Fallon, MD - University of Edinburgh, Scotland, UK |
|||
|
10:20 am |
Kenneth C.H. Fearon Keynote Lectureship Denis Guttridge, PhD - Medical University of South Carolina, USA |
|||
|
Cutting Edge Research in Cancer Cachexia |
||||
|
Co-Chairs: TBN |
||||
|
11:30 am |
Cutting Edge Talk 1 from abstracts |
|||
|
11:35 am |
Cutting Edge Talk 2 from abstracts |
|||
|
11:40 am |
Cutting Edge Talk 3 from abstracts |
|||
|
11:45 am |
Cutting Edge Talk 4 from abstracts |
|||
|
11:50 am |
Cutting Edge Talk 5 from abstracts |
|||
|
11:55 pm |
Cutting Edge Talk 6 from abstracts |
|||
|
12:00 pm |
Lunch Break |
|||
|
Immunometabolism of Cancer Cachexia |
||||
|
Co-Chairs: TBN |
||||
|
1:30 pm |
Immune checkpoint inhibition and cancer cachexia Chris Coss, PhD - The Ohio State University, USA |
|||
|
2:00 pm |
HMGB1 in cancer cachexia Marco Bianchi, MD - San Raffaele University, ITALY |
|||
|
2:30 pm |
Short talk: Hepatic metabolism, IL-6, cancer cachexia Aaron Grossberg, MD PhD - Oregon Health & Science University, USA |
|||
|
2:45 pm |
Short talk selected from abstract submissions |
|||
|
3:00 pm |
Break |
|||
|
Novel targetable pathways, novel therapeutic strategies |
||||
|
Co-Chairs: TBN |
||||
|
3:30 pm |
A novel target for tumor growth and muscle wasting Marco Sandri, PhD - University of Padova, ITALY |
|||
|
4:00 pm |
Long noncoding RNAs in the regeneration of aging muscle Miriam Gorospe, PhD – National Institute on Aging, National Institutes of Health, USA |
|||
|
4:30 pm |
COVID, Cachexia and Cancer David Glass, MD, PhD – Regeneron, USA |
|||
|
5:00 pm |
GDF15 in cancer cachexia and beyond Bei Zhang, PhD - Pfizer, USA |
|||
|
5:30 PM |
Short talk selected from abstract submissions |
|||
|
5:45 PM |
Presentation of awards |
|||
|
6:00 PM |
Closing Remarks
Teresa Zimmers, PhD Oregon Health & Science University, USA and Andrew Judge, PhD University of Florida, USA |
|||
*Certain social events, including the whiskey tasting, dinner and Cèilidh require additional fees.